XML 84 R41.htm IDEA: XBRL DOCUMENT v3.25.4
Revenue (Tables)
 12 Months Ended
Dec. 31, 2025
Revenue from Contract with Customer [Abstract]  
Revenue by product
Revenue by product are summarized as follows:
 For the Years Ended December 31,
 202520242023
(In millions)United
States		Rest of
World		TotalUnited
States		Rest of
World		TotalUnited
States		Rest of
World		Total
Multiple Sclerosis:
TECFIDERA$168.5 $511.2 $679.7 $169.2 $797.9 $967.1 $263.1 $749.4 $1,012.5 
VUMERITY651.2 95.6 746.8 538.6 89.4 628.0 512.1 64.2 576.3 
Total Fumarate819.7 606.8 1,426.5 707.8 887.3 1,595.1 775.2 813.6 1,588.8 
AVONEX482.9 212.6 695.5 451.3 256.2 707.5 536.7 274.3 811.0 
PLEGRIDY104.9 145.2 250.1 111.4 149.1 260.5 126.2 168.5 294.7 
Total Interferon587.8 357.8 945.6 562.7 405.3 968.0 662.9 442.8 1,105.7 
TYSABRI965.0 700.4 1,665.4 920.0 795.0 1,715.0 997.9 879.0 1,876.9 
FAMPYRA(1)
— 1.4 1.4 — 71.7 71.7 — 90.5 90.5 
Subtotal: Multiple Sclerosis2,372.5 1,666.4 4,038.9 2,190.5 2,159.3 4,349.8 2,436.0 2,225.9 4,661.9 
Rare Disease:
SPINRAZA625.5 921.3 1,546.8 625.7 947.5 1,573.2 610.5 1,130.7 1,741.2 
SKYCLARYS(2)
310.6 209.9 520.5 301.1 81.4 382.5 55.9 — 55.9 
QALSODY(3)
30.1 56.8 86.9 20.9 11.5 32.4 5.8 0.1 5.9 
Subtotal: Rare Disease966.2 1,188.0 2,154.2 947.7 1,040.4 1,988.1 672.2 1,130.8 1,803.0 
Biosimilars:
BENEPALI— 453.2 453.2 — 479.1 479.1 — 438.8 438.8 
IMRALDI— 190.2 190.2 — 213.1 213.1 — 222.1 222.1 
FLIXABI— 52.6 52.6 — 63.2 63.2 — 77.4 77.4 
BYOOVIZ13.0 19.4 32.4 23.0 13.6 36.6 29.2 2.5 31.7 
TOFIDENCE0.7 — 0.7 1.1 — 1.1 — — — 
Subtotal: Biosimilars13.7 715.4 729.1 24.1 769.0 793.1 29.2 740.8 770.0 
Other:
ZURZUVAE195.1 — 195.1 72.2 — 72.2 1.6 — 1.6 
Other(4)
0.4 1.7 2.1 2.8 7.5 10.3 2.4 7.8 10.2 
Subtotal: Other195.5 1.7 197.2 75.0 7.5 82.5 4.0 7.8 11.8 
Total product revenue, net$3,547.9 $3,571.5 $7,119.4 $3,237.3 $3,976.2 $7,213.5 $3,141.4 $4,105.3 $7,246.7 
(1) Effective January 1, 2025, our collaboration and license agreement for FAMPYRA global commercialization rights was terminated.
(2) SKYCLARYS became commercially available in the E.U. during the first quarter of 2024.
(3) QALSODY became commercially available in the E.U. during the second quarter of 2024.
(4) Other includes FUMADERM and ADUHELM.
Analysis of change in reserves
An analysis of the change in reserves for discounts and allowances is summarized as follows:
As of December 31, 2025
(In millions)DiscountsContractual
Adjustments		ReturnsTotal
Balance, December 31, 2024$162.7 $880.8 $48.1 $1,091.6 
Current provisions relating to sales in current year832.4 2,773.1 31.9 3,637.4 
Adjustments relating to prior years2.2 (83.4)0.7 (80.5)
Payments/credits relating to sales in current year(728.3)(1,905.8)(1.7)(2,635.8)
Payments/credits relating to sales in prior years(153.3)(618.6)(30.0)(801.9)
Balance, December 31, 2025$115.7 $1,046.1 $49.0 $1,210.8 
As of December 31, 2024
(In millions)DiscountsContractual
Adjustments		ReturnsTotal
Balance, December 31, 2023$173.3 $857.1 $31.6 $1,062.0 
Current provisions relating to sales in current year824.2 2,687.5 23.6 3,535.3 
Adjustments relating to prior years8.0 (38.7)14.2 (16.5)
Payments/credits relating to sales in current year(670.9)(1,989.7)(0.6)(2,661.2)
Payments/credits relating to sales in prior years(171.9)(635.4)(20.7)(828.0)
Balance, December 31, 2024$162.7 $880.8 $48.1 $1,091.6 
As of December 31, 2023
(In millions)DiscountsContractual
Adjustments		ReturnsTotal
Balance, December 31, 2022$153.8 $857.7 $23.5 $1,035.0 
Current provisions relating to sales in current year735.6 2,720.1 19.0 3,474.7 
Adjustments relating to prior years(0.4)(38.4)19.2 (19.6)
Payments/credits relating to sales in current year(572.9)(1,944.8)(2.1)(2,519.8)
Payments/credits relating to sales in prior years(142.8)(737.5)(28.0)(908.3)
Balance, December 31, 2023$173.3 $857.1 $31.6 $1,062.0 
Total reserves included in consolidated balance sheet
The total reserves above, which are included in our consolidated balance sheets, are summarized as follows:
 As of December 31,
(In millions)20252024
Reduction of accounts receivable$210.4 $154.1 
Component of accrued expense and other1,000.4 937.5 
Total revenue-related reserves$1,210.8 $1,091.6 
Revenues from anti-CD20 therapeutic programs
Revenue from anti-CD20 therapeutic programs is summarized in the table below. For purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.
 For the Years Ended December 31,
(In millions)202520242023
Royalty revenue on sales of OCREVUS$1,414.9 $1,339.5 $1,266.2 
Biogen's share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO420.2 392.0 409.4 
Other revenue from anti-CD20 therapeutic programs25.5 18.4 14.0 
Total revenue from anti-CD20 therapeutic programs$1,860.6 $1,749.9 $1,689.6 
Revenue from anti-CD20 therapeutic programs is summarized as follows:
 For the Years Ended December 31,
(In millions)202520242023
Royalty revenue on sales of OCREVUS$1,414.9 $1,339.5 $1,266.2 
Biogen's share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO420.2 392.0 409.4 
Other revenue from anti-CD20 therapeutic programs25.5 18.4 14.0 
Total revenue from anti-CD20 therapeutic programs$1,860.6 $1,749.9 $1,689.6 
Other revenues
Contract manufacturing, royalty and other revenue is summarized as follows:
 For the Years Ended December 31,
(In millions)202520242023
Contract manufacturing revenue$679.4 $592.1 $848.2 
Royalty and other revenue53.5 60.5 51.1 
Total contract manufacturing, royalty and other revenue$732.9 $652.6 $899.3